See more : The Indian Hotels Company Limited (INDHOTEL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Evaxion Biotech A/S (EVAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evaxion Biotech A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MRV Engenharia e Participações S.A. (MRVE3.SA) Income Statement Analysis – Financial Results
- AGBA Acquisition Limited (AGBAR) Income Statement Analysis – Financial Results
- Bank AlJazira (1020.SR) Income Statement Analysis – Financial Results
- Orrön Energy AB (publ) (LNDNF) Income Statement Analysis – Financial Results
- Sekerbank T.A.S. (SKBNK.IS) Income Statement Analysis – Financial Results
Evaxion Biotech A/S (EVAX)
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 73.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 112.00 | 571.32K | 343.45K | 105.72K | 80.98K | 73.93K |
| Gross Profit | 72.89K | -571.32K | -343.45K | -105.72K | -80.98K | -73.93K |
| Gross Profit Ratio | 99.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.92M | 17.06M | 19.58M | 10.90M | 8.22M | 3.73M |
| General & Administrative | 10.35M | 8.21M | 6.25M | 5.67M | 2.63M | 1.88M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.35M | 8.21M | 6.25M | 5.67M | 2.63M | 1.88M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 15.00K |
| Operating Expenses | 22.25M | 25.26M | 25.83M | 16.57M | 10.86M | 5.63M |
| Cost & Expenses | 22.27M | 25.26M | 25.83M | 16.57M | 10.86M | 5.63M |
| Interest Income | 154.00K | 2.83M | 2.04M | 216.00K | 9.00K | 2.00K |
| Interest Expense | 897.00K | 1.51M | 915.00K | 223.00K | 1.22M | 698.00K |
| Depreciation & Amortization | 615.95K | 571.32K | 343.45K | 105.72K | 80.98K | 73.93K |
| EBITDA | -21.40M | -22.58M | -24.17M | -16.46M | -11.90M | -6.18M |
| EBITDA Ratio | -29,319.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.20M | -25.26M | -25.83M | -16.57M | -10.86M | -5.63M |
| Operating Income Ratio | -30,406.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -718.00K | 1.32M | 1.12M | -7.00K | -1.16M | -636.93K |
| Income Before Tax | -22.92M | -23.94M | -24.71M | -16.58M | -12.02M | -6.27M |
| Income Before Tax Ratio | -31,390.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -791.22K | -772.00K | -178.00K | -1.56M | -825.00K | -735.00K |
| Net Income | -22.13M | -23.17M | -24.53M | -15.02M | -11.20M | -5.54M |
| Net Income Ratio | -30,308.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.11 | -9.80 | -12.58 | -9.27 | -6.91 | -2.88 |
| EPS Diluted | -8.11 | -9.80 | -12.58 | -9.27 | -6.91 | -2.88 |
| Weighted Avg Shares Out | 2.73M | 2.36M | 1.95M | 1.62M | 1.62M | 1.92M |
| Weighted Avg Shares Out (Dil) | 2.73M | 2.36M | 1.95M | 1.62M | 1.62M | 1.92M |
Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Conference Call August 22, 2023 10:00 AM ET Company Participants Per Norlen - Chief Executive Officer Jesper Nyegaard Nissen - Chief Operating Officer and Interim Chief Financial Officer Conference Call Participants Thomas Flaten...
Evaxion Announces Business Update and Second Quarter 2023 Financial Results
Promising clinical data from Phase 1 and 2a studies with EVX-01 and EVX-02 were presented at AACR and ASCO in Q2 2023 A novel proprietary genetic vaccine adjuvant was presented at Evaxion's R&D Day in May. The technology is an...
Evaxion announces financing commitments totaling up to USD 20 million with Negma Group
Copenhagen, DENMARK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that it has entered into a binding agreement for a...
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
COPENHAGEN, Denmark, July 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon...
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase...
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that they expect to present data from their two clinical trials...
Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today
High volume penny stocks to watch before next week. The post Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study
Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.
Good Penny Stocks to Add to Your Buy List? 3 to Watch
Which penny stocks are on your buy list right now? The post Good Penny Stocks to Add to Your Buy List?
Why Is Evaxion Biotech (EVAX) Stock Up Today?
Today's price action (prior to the Federal Reserve's rate hike decision at least) has been broadly positive. But for investors in Evaxion Biotech (NASDAQ: EVAX ), it's been a heck of a day.
Source: https://incomestatements.info
Category: Stock Reports